Peptide-based immunotherapy of systemic lupus erythematosus

Autoimmunity Reviews

Volumn 3, Issue 1, 2004, Pages 16-24

  Monneaux, Fanny ^a   Muller, Sylviane ^a  

^a INSTITUT DE BIOLOGIE MOLÉCULAIRE ET CELLULAIRE   (France)

Author keywords

Altered peptide ligand; Antigen specific therapy; Immunomodulation; Systemic lupus erythematosus; T cell

Indexed keywords

COMPLEMENTARY DETERMINING REGION PROTEIN; HISTONE; HISTONE H2B; HISTONE H4; PEPTIDE DERIVATIVE; PROTEIN; PROTEIN CONS; PROTEIN P34; PROTEIN P58; PROTEIN P84; RIBONUCLEOPROTEIN; UNCLASSIFIED DRUG;

AUTOIMMUNITY; COMPLEMENTARITY DETERMINING REGION; DRUG EFFECT; DRUG SCREENING; DRUG SYNTHESIS; ELUTION; EX VIVO STUDY; HUMAN; IMMUNE SYSTEM; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; IMMUNOTHERAPY; MAJOR HISTOCOMPATIBILITY COMPLEX; NONHUMAN; PATHOGENESIS; REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE;

EID: 1042278947     PISSN: 15689972     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1568-9972(03)00061-2     Document Type: Review

References (41)

1. Mosca M., Ruiz-Irastorza G., Khamashta M.A., Hughes G.R.V. Treatment of systemic lupus erythematosus. Intern Immununopharmacol. 1:2001;1065-1075.
2. Zandman-Goddard G., Shoenfeld Y. Novel approaches to therapy for systemic lupus erythematosus. Eur J Int Med. 11:2000;130-134.
3. Zonana-Nacach A., Barr S.G., Magder L.S., Petri M. Damage in systemic lupus erythematosus and its association with corticosteroids. Arthritis Rheum. 43:2000;1801-1808.
4. Singh R.R. The potential use of peptides and vaccination to treat systemic lupus erythematosus. Curr Op Rheumatol. 12:2000;399-406.
5. Kaliaperumal A., Mohan C., Wu W., Datta S.K. Nucleosomal peptide epitopes for nephritis-inducing helper T cells of murine lupus. J Exp Med. 183:1996;2459-2470.
6. Lu L., Kaliyaperumal A., Boumpas D.T., Datta S.K. Major peptide autoepitopes for nucleosome-specific T cells of human lupus. J Clin Invest. 104:1999;345-355.
7. Stemmer C., Briand J-P., Muller S. Mapping of linear histone regions exposed at the surface of the nucleosome in solution. J Mol Biol. 273:1997;52-60.
8. Muller S., Bonnier D., Thiry M., Van Regenmortel M.H. Reactivity of autoantibodies in systemic lupus erythematosus with synthetic core histone peptides. Int Arch Allergy Appl Immunol. 89:1989;288-296.
9. Sabbatini A., Bombardieri S., Migliorini P. Autoantibodies from patients with systemic lupus erythematosus bind a shared sequence of SmD and Epstein-Barr virus-encoded nuclear antigen EBNA I. Eur J Immunol. 23:1993;1146-1152.
10. Riemekasten G., Marell J., Trebeljahr G., Klein R., Hausdorf G., Häupl T., et al. A novel epitope on the C-terminus of SmD1 is recognized by the majority of sera from patients with systemic lupus erythematosus. J Clin Invest. 102:1998;754-763.
11. lpr and (NZBxNZW)F1 lupus mice. Intern Immunol. 13:2001;1155-1163.
12. Riemekasten G., Weiss C., Schneider S., Thiel A., Bruns A., Schumann F., et al. T cell reactivity against the SmD1(83-119) C terminal peptide in patients with systemic lupus erythematosus. Ann Rheum Dis. 61:2002;779-785.
13. Riemekasten G., Kawald A., Weiss C., Meine A., Marell J., Klein R., et al. Strong acceleration of murine lupus by injection of the SmD1(83-119) peptide. Arthritis Rheum. 44:2001;2435-2445.
14. Talken B.L., Schäfermeyer K.R., Bailey C.W., Lee D.R., Hoffman R.W. T cell epitope mapping of the Smith antigen reveals that highly conserved Smith antigen motifs are the dominant target of the T cell immunity in systemic lupus erythematosus. J Immunol. 167:2001;562-568.
15. Eur J Immunol. 30:2000;2191-2200.
16. Monneaux F., Lozano J.M., Patarroyo M.E., Briand J.-P., Muller S. T cell recognition and therapeutic effects of a phosphorylated synthetic peptide of the 70 K snRNP protein administered in MRL/lpr lupus mice. Eur J Immunol. 33:2003;287-296.
17. Greidinger E.L., Foecking M.F., Schäfermeyer K.M., Bailey C.W., Primm S.L., Lee D.R., et al. T cell immunity in connective tissue disease patients targets the RNA binding domain of the U1-70 kD small nuclear ribonucleoprotein. J Immunol. 169:2002;3429-3437.
18. Okubo M., Kokubun M., Nishimaki T., Kasukawa R., Ohto H., Yamamoto K., et al. T cell epitope mapping of U1-A RNP. Arthritis Rheum. 38:1995;1170-1172.
19. Barakat S., Briand J.-P., Abuaf N., Van Regenmortel M.H., Muller S. Mapping of epitope on U1 snRNP polypeptide A with synthetic peptides and autoimmune sera. Clin Exp Immunol. 86:1991;71-78.
20. Singh R.R., Ebling F.M., Sercarz E.E., Hahn B.H. Immune tolerance to autoantibody-derived peptides delays development of autoimmunity in murine lupus. J Clin Invest. 96:1995;2990-2996.
21. Singh R.R., Hahn B.H., Tsao B.P., Ebling F.M. Evidence for multiple mechanisms of polyclonal T cell activation in murine lupus. J Clin Invest. 102:1998;1841-1849.
22. Freed J.H., Marrs A., VanderWall J., Cohen P.L., Eisenberg R.A. MHC class II-bound self peptides from autoimmune MRL/lpr mice reveal potential T cell epitopes for autoantibody production in murine systemic lupus erythematosus. J Immunol. 164:2002;4697-4705.
23. Suh C.-H., Freed J.H., Cohen P.L. T cell reactivity to MHC class II-bound self peptides in systemic lupus erythematosus-prone MRL/lpr mice. J Immunol. 170:2003;2229-2235.
24. Kaliaperumal A., Michaels M.A., Datta S.K. Naturally processed chromatin peptides reveal a major autoepitope that primes pathogenic T and B cells of lupus. J Immunol. 168:2002;2530-2537.
25. Kaliaperumal A., Michaels M.A., Datta S.K. Antigen-specific therapy of murine lupus nephritis using nucleosomal peptides: tolerance spreading impairs pathogenic function of autoimmune T and B cells. J Immunol. 162:1999;5775-5783.
26. Wu H.Y., Ward F.J., Staines N.A. Histone peptide-induced nasal tolerance: suppression of murine lupus. J Immunol. 169:2002;1126-1134.
27. Jouanne C., Avrameas S., Payelle-Brogard B. A peptide derived from a polyreactive monoclonal anti-DNA natural antibody can modulate lupus development in (NZBxNZW)F1 mice. Immunology. 96:1999;333-339.
28. Eilat E., Zinger H., Nyska A., Mozes E. Prevention of systemic lupus erythematosus-like disease in (NZBxNZW)F1 mice by treating with CDR1- and CDR3-based peptides of a pathogenic autoantibody. J Clin Immunol. 20:2000;268-278.
29. Hahn B.H., Singh R.R., Wong W.K., Tsao B.P., Bulpitt K., Ebling F.M. Treatment with a consensus peptide based on amino acid sequences in autoantibodies prevents T cell activation by autoantigens and delays disease onset in murine lupus. Arthritis Rheum. 44:2001;432-441.
30. Zinger H., Eilat E., Meshorer A., Mozes E. Peptides based on the complementarity-determining regions of a pathogenic autoantibody mitigate lupus manifestations of (NZBxNZW)F1 mice via active suppression. Intern Immunol. 15:2003;205-214.
31. Mézière C., Viguier M., Dumortier H., Lo-Man R., Leclerc C., Guillet J.G., et al. In vivo T helper cell response to retro-inverso peptidomimetics. J Immunol. 159:1997;3230-3237.
32. Hutchings P., Cooke A. Protection from insulin dependent diabetes mellitus afforded by insulin antigens in complete Freund's adjuvant depends on route of administration. J Autoimmun. 11:1998;127-130.
33. Von Herrath M.G., Coon B., Wolfe T. Tolerance induction with agonist peptides recognized by autoagressive lymphocytes is transient: therapeutic potential for type 1 diabetes is limited and depends on time-point of administration, choice of epitope and adjuvant. J Autoimmun. 16:2001;193-199.
34. Van Bilsen J.H.M., Wagenaar-Hilbers J.P.A., Van der Cammen M.J.F., Van Dijk M.E.A., Van Eden W., Wauben M.H.M. Successful immunotherapy with matrix metalloproteinase-derived peptides in adjuvant arthritis depends on the timing of peptide administration. Arthritis Res. 4:2002;R2.1-R2.8.
35. Asano M., Toda M., Sakaguchi N., Sagaguchi S. Autoimmune disease as a consequence of developing abnormality of a T-cell subpopulation. J Exp Med. 184:1996;387-396.
36. Prakken B.J., Roord S., van Kooten P.J.S., Wagenaar J.P.A., van Eden W., Albani S., et al. Inhibition of adjuvant-induced arthritis by interleukin-10-driven regulatory cells induced via nasal administration of a peptide analog of an arthritis-related heat-shock protein 60 T cell epitope. Arthritis Rheum. 46:2002;1937-1946.
37. Ulmansky R., Cohen C.J., Szafer F., Moallem E., Fridlender Z.G., Kashi Y., et al. Resistance to adjuvant arthritis is due to protective antibodies against heat shock protein surface epitopes and the induction of IL-10 secretion. J Immunol. 168:2002;6463-6469.
38. Yin Z., Bahtiyar G., Zhang N., Liu L., Zhu P., Robert M.E., et al. IL-10 regulates murine lupus. J Immunol. 169:2002;2148-2155.
39. H-derived major histocompatibility complex class I-binding epitopes activates cytototix T cells that ablate autoantibody-producing B cells and inhibit lupus. J Exp Med. 196:2002;731-741.
40. Wucherpfenning K.W. Insights into autoimmunity gained from structural analysis of MHC-peptide complexes. Curr Op Immunol. 13:2001;650-656.
41. Anderton S.M. Peptide-based immunotherapy of autoimmunity: a path of puzzles, paradoxes and possibilities. Immunology. 104:2001;367-376.